Skip to main content
Caplight Logo









Minovia Therapeutics

Minovia Therapeutics

Private
HaifaHealthcare & Life Scienceshttps://minoviatx.com/

Last Round

M&A

Jan 30, 2026

Total Funding Raised

$36M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Minovia Therapeutics is a clinical-stage biotechnology company that develops novel therapies to treat mitochondrial diseases and combat age-related decline using its proprietary Mitochondrial Augmentation Therapy (MAT) platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

mitochondrial cell therapyMitochondrial Augmentation TechnologyMAT platformautologous cell therapymitochondrial dysfunctionmitochondrial diseasestem cell therapymyelodysplastic syndromeMDSlongevity biotechPearson syndromeregenerative medicinerare genetic disordersmitochondrial biomarkerspatient stratificationOrphan Drug designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Minovia Therapeutics Comparables

Compare Minovia Therapeutics with similar companies based on industry and business-model similarity.

Minovia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PAEAN Biotechnology
80%
cellvie
78%
Taiwan Mitochondrion Applied Technology Co., Ltd.
77%

Minovia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AJan 30, 2026
GrantAug 27, 2025
Corporate FundingJul 30, 2021
Series ADec 1, 2018

Key People

Founding team and executive leadership

Natalie Yivgi-Ohana

CEO

Executive Team

Minovia Therapeutics Investors

Notable investors and investment history

Minovia Therapeutics investors
InvestorRounds
Launch One Acquisition Corp.M&A
Countdown For A Cure FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Open roles increased to 12, 3x the trailing average.

  • Jul 20, 2026

    Open roles increased from 0 to 12, representing 50% of headcount.

Minovia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Minovia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Minovia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHaifa
Employee Range24
Year Founded2012
Last FundingJan 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?